Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rE-4 in Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and/or Sulfonylurea
CTR20170495Phase 3Active
- Sponsor
- CSPC Pharmaceutical Group
- Start
- Nov 2017
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant exendin-4 in type 2 diabetes mellitus (T2DM), sponsored by CSPC Pharmaceutical Group. Started Nov 2017; status: active.
02
Drugs
recombinant exendin-4
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20170495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170495.